GRAIL, Inc. (NASDAQ: GRAL) experienced a dramatic 24-hour plunge of 47.49% in post-market trading on Thursday. The severe drop in share price followed the release of pivotal clinical trial data and quarterly financial results.

The stock's steep decline came after the company announced that its landmark NHS-Galleri trial for the Galleri multi-cancer early detection test failed to meet its primary endpoint. The trial did not achieve a statistically significant reduction in combined Stage III and Stage IV cancer diagnoses, representing a significant setback for the company's flagship product despite showing positive secondary outcomes in early-stage detection.

Concurrently, GRAIL reported fourth-quarter earnings that exceeded analyst expectations, with a loss of $2.44 per share beating the consensus estimate of $2.73. However, quarterly sales of $43.597 million slightly missed expectations. The company also announced plans to extend the trial's follow-up period by 6-12 months, which may delay regulatory pathways and commercial timelines for the Galleri test.